Cancer Biomarkers

Scope & Guideline

Advancing the Science of Cancer Biomarkers.

Introduction

Delve into the academic richness of Cancer Biomarkers with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1574-0153
PublisherIOS PRESS
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 2005 to 2024
AbbreviationCANCER BIOMARK / Cancer Biomark.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressNIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS

Aims and Scopes

Cancer Biomarkers focuses on the exploration and identification of biomarkers that can aid in the diagnosis, prognosis, and treatment of various cancers. The journal emphasizes the integration of molecular biology, genomics, and bioinformatics to discover new potential biomarkers and therapeutic targets.
  1. Biomarker Discovery and Validation:
    The journal extensively publishes research aimed at discovering novel biomarkers that can be used for early detection, diagnosis, and prognosis of different cancer types.
  2. Molecular Mechanisms of Cancer:
    Research articles often focus on elucidating the molecular pathways and mechanisms through which identified biomarkers influence cancer progression and response to therapies.
  3. Genomic and Epigenomic Studies:
    A significant focus is placed on genomic and epigenomic alterations in cancer, including DNA methylation patterns and gene expression profiles that correlate with clinical outcomes.
  4. Machine Learning and Bioinformatics:
    The journal supports the application of machine learning and bioinformatics tools to analyze complex datasets and identify biomarkers with clinical relevance.
  5. Immune Biomarkers and Microenvironment:
    Research exploring the role of immune-related biomarkers and the tumor microenvironment in cancer progression and treatment response is a key area of focus.
Recent publications in Cancer Biomarkers indicate a dynamic evolution in research themes, with several emerging areas gaining traction. These trends reflect advancements in technology and a growing understanding of cancer biology, leading to innovative approaches in biomarker research.
  1. Long Non-Coding RNAs (lncRNAs):
    Research on lncRNAs is rapidly increasing, highlighting their potential roles as biomarkers for various cancers, particularly in regulating gene expression and cancer progression.
  2. Immune Checkpoint Inhibitors:
    The exploration of biomarkers related to immune checkpoint inhibitors is trending, reflecting the rise of immunotherapy as a cornerstone in cancer treatment.
  3. Multi-Omics Approaches:
    There is a growing trend towards multi-omics studies, integrating genomic, transcriptomic, proteomic, and metabolomic data to provide comprehensive insights into cancer biology and biomarker discovery.
  4. Artificial Intelligence in Biomarker Discovery:
    The use of AI and machine learning algorithms to analyze complex datasets and improve biomarker identification and validation is an emerging theme, indicating a shift towards data-driven research methodologies.
  5. Tumor Microenvironment Studies:
    Research focusing on the tumor microenvironment and its impact on cancer progression and therapy response is gaining prominence, emphasizing the interplay between cancer cells and their surrounding environment.

Declining or Waning

While Cancer Biomarkers continues to thrive in various research areas, certain themes have shown a noticeable decline in publication frequency over recent years. This waning interest may reflect shifts in research priorities or advancements in technology that have rendered previous approaches less prominent.
  1. Traditional Tumor Markers:
    Research focusing on conventional tumor markers such as CEA or CA 19-9 appears to be declining as novel biomarkers and more sophisticated molecular techniques gain prominence.
  2. Single Biomarker Studies:
    There has been a shift away from studies focusing solely on single biomarkers, as the field moves towards multi-biomarker panels and integrative approaches that consider the complexity of cancer biology.
  3. Invasive Diagnostic Techniques:
    Research on invasive diagnostic methods is waning in favor of non-invasive liquid biopsy techniques that utilize circulating biomarkers for cancer detection and monitoring.
  4. Chemotherapy Response Predictors:
    The exploration of predictive biomarkers specifically for chemotherapy response has decreased, likely due to a broader focus on immunotherapy and targeted therapies.
  5. Non-specific Biomarkers:
    Interest in non-specific biomarkers that lack clear associations with particular cancer types or outcomes has diminished as the field emphasizes more precise and context-specific biomarker identification.

Similar Journals

CANCER SCIENCE

Pioneering discoveries in cancer biochemistry and genetics.
Publisher: WILEYISSN: 1347-9032Frequency: 12 issues/year

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

Cancer Biology & Medicine

Elevating the Standards of Cancer Biology
Publisher: CHINA ANTI-CANCER ASSOCISSN: 2095-3941Frequency: 4 issues/year

Cancer Biology & Medicine is a distinguished Open Access journal published by the China Anti-Cancer Association, dedicated to advancing research and understanding in the fields of Cancer Research and Oncology. Since its inception in 2012, the journal has provided a vital platform for the dissemination of high-quality research, evidenced by its impressive ranking within the Q1 and Q2 categories of oncology and cancer research as of 2023. With a significant impact factor and a Scopus ranking of #64 in Medicine/Oncology and #55 in Biochemistry, Genetics, and Molecular Biology, it plays a crucial role in shaping the future of cancer biology. By offering open access to its content, the journal ensures that pivotal research findings are readily available to researchers, professionals, and students globally, thereby fostering collaboration and innovation in cancer research. Situated in Tianjin, China, this journal is poised at the frontier of oncology research, making a significant impact through its rigorous peer-reviewed articles that address critical challenges in the field.

Oncologie

Transforming cancer treatment through rigorous research.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

NEOPLASIA

Uncovering breakthroughs in cancer biology and treatment.
Publisher: ELSEVIER SCIENCE INCISSN: 1476-5586Frequency: 12 issues/year

NEOPLASIA is an esteemed open-access journal dedicated to advancing the field of oncology, published by Elsevier Science Inc. since 1999. With an impressive impact factor and recognition as a Q1 journal in Cancer Research for 2023, it holds a significant position within the scientific community, specifically ranking in the 74th percentile globally in the categories of Biochemistry, Genetics, and Molecular Biology. NEOPLASIA seeks to provide a comprehensive platform for innovative research, covering a wide array of topics in cancer biology, treatment methodologies, and therapeutic advancements. Researchers, professionals, and students are encouraged to utilize this resource, which is easily accessible to foster collaboration and stimulate progress in cancer research. As it converges its efforts towards the future of oncology, this journal is poised to remain at the forefront of transformative discoveries that shape our understanding and treatment of cancer.

Molecular and Clinical Oncology

Advancing cancer research for a healthier tomorrow.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

CANCER GENE THERAPY

Unleashing the Power of Molecular Medicine in Oncology
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

CANCER BIOLOGY & THERAPY

Empowering breakthroughs in cancer biology and therapy.
Publisher: TAYLOR & FRANCIS INCISSN: 1538-4047Frequency: 12 issues/year

CANCER BIOLOGY & THERAPY is a premier open-access journal published by Taylor & Francis Inc, dedicated to advancing the field of cancer research and treatment. Since its inception in 2002, the journal has evolved to provide a platform for innovative research and groundbreaking findings, addressing critical aspects of cancer biology, pharmacology, and molecular medicine. With an impressive impact factor and recognition as a Q2 journal in vital categories such as Cancer Research, Oncology, and Pharmacology, it holds significant standing in Scopus rankings, reflecting its influence and commitment to disseminating high-quality research. Offering researchers, professionals, and students a wealth of knowledge, CANCER BIOLOGY & THERAPY stands at the forefront of the fight against cancer, presenting the latest developments and therapeutic strategies vital for improving patient outcomes. Accessible to all since 2022, this journal is a must-read for anyone involved in the multifaceted arena of cancer research and treatment.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Unraveling the Complexities of Cancer Biology
Publisher: ELSEVIERISSN: 0304-419XFrequency: 4 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.

Cancer Genomics & Proteomics

Innovating diagnostics and therapeutics with cutting-edge research.
Publisher: INT INST ANTICANCER RESEARCHISSN: 1109-6535Frequency: 6 issues/year

Cancer Genomics & Proteomics is a pivotal journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of cancer genomics and proteomics. Established in 2004 and running until 2024, this journal provides a vital platform for the dissemination of high-quality research that explores genetic and protein interactions in cancer, thereby fostering innovations in diagnostics and therapeutics. The journal boasts a commendable Q2 ranking in Biochemistry and Genetics and is recognized in the Q3 tier for its contributions to Cancer Research and Molecular Biology, reflecting its growing impact in these dynamic fields. Operating out of Greece, it engages a diverse audience, including researchers, clinicians, and students, by sharing significant findings and methodological advancements in the realm of cancer studies. While currently not an open-access publication, Cancer Genomics & Proteomics remains committed to enriching scientific dialogue and collaboration with its insightful articles and reviews.

INTERNATIONAL JOURNAL OF ONCOLOGY

Advancing cancer research for a healthier tomorrow.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.